C-terminal exon 5.4 of runx1/aml1
AssigneeJulius-Maximilians-Universitaet Wuerzburg
InventorsStefan Gattenloehner, Alexander Marx
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel C-terminal exon of RUNX1/AML1, its nucleic acid sequence, its peptide and a full length amino acid sequence comprising the novel C-terminal exon. Furthermore, the invention is directed to an antibody against the C-terminal exon of RUNX1/AML1, a pharmaceutical composition for the treatment of various diseases, among others various tumours and the use of the C-terminal exon for the manufacture of a medicament. The C-terminal exon may also be used for the inhibition of cellular growth and/or induction of apoptosis. Furthermore, the invention relates to a method and a kit for diagnosing a disease, both using the C-terminal exon.
Claims12
A C-terminal exon of RUNX1/AML1, wherein the exon is defined by the nucleic acid sequence of AAC AGT TGT GAT TAC TTC AGG TTT CAC CAG ATG CCT TGA (SEQ ID NO:1) and/or functional variants thereof.
A peptide of a C-terminal exon of RUNX1/AML1, wherein the peptide is defined by the amino acid sequence of NSCDYFRFHQMP (SEQ ID NO:2) and/or functional variants thereof.
(canceled)
An antibody which is directed against a peptide sequence of the C-terminal exon of RUNX1/AML1 of SEQ ID NO:2 and/or functional variants thereof.
A pharmaceutical composition comprising a nucleic acid sequence and/or a peptide sequence of the C-terminal exon of RUNX1/AML1 of SEQ ID NO:1 or 2, an antibody against SEQ ID NO:2 and/or functional variants thereof.
11-13. (canceled)
Dependencies are inferred from the claim text.